Commentary on Sertkaya et al. and Larson et al.
- Published in:
- Clinical Trials, 2016, v. 13, n. 2, p. 137, doi. 10.1177/1740774515626410
- By:
- Publication type:
- Article
Works matching IS 17407745 AND DT 2016 AND VI 13 AND IP 2
Results: 16
1
2
Response to Magnus and Wilfond.
- Published in:
- Clinical Trials, 2016, v. 13, n. 2, p. 244, doi. 10.1177/1740774515626149
- By:
- Publication type:
- Article
3
Recruiting and retaining young adults in a weight gain prevention trial: Lessons learned from the CHOICES study.
- Published in:
- Clinical Trials, 2016, v. 13, n. 2, p. 205, doi. 10.1177/1740774515605084
- By:
- Publication type:
- Article
4
Avoiding bias and incorrect confidence interval coverage in prescription drug labeling.
- Published in:
- Clinical Trials, 2016, v. 13, n. 2, p. 199, doi. 10.1177/1740774515615097
- By:
- Publication type:
- Article
5
Lessons learned: Infrastructure development and financial management for large, publicly funded, international trials.
- Published in:
- Clinical Trials, 2016, v. 13, n. 2, p. 127, doi. 10.1177/1740774515625974
- By:
- Publication type:
- Article
6
Key cost drivers of pharmaceutical clinical trials in the United States.
- Published in:
- Clinical Trials, 2016, v. 13, n. 2, p. 117, doi. 10.1177/1740774515625964
- By:
- Publication type:
- Article
7
A comparison of confidence interval methods for the intraclass correlation coefficient in community-based cluster randomization trials with a binary outcome.
- Published in:
- Clinical Trials, 2016, v. 13, n. 2, p. 180, doi. 10.1177/1740774515606377
- By:
- Publication type:
- Article
8
Recruiting community health centers into pragmatic research: Findings from STOP CRC.
- Published in:
- Clinical Trials, 2016, v. 13, n. 2, p. 214, doi. 10.1177/1740774515608122
- By:
- Publication type:
- Article
9
Risks of phase I research with healthy participants: A systematic review.
- Published in:
- Clinical Trials, 2016, v. 13, n. 2, p. 149, doi. 10.1177/1740774515602868
- By:
- Publication type:
- Article
10
Fallacies of last observation carried forward analyses.
- Published in:
- Clinical Trials, 2016, v. 13, n. 2, p. 161, doi. 10.1177/1740774515602688
- By:
- Publication type:
- Article
11
Sample size under the additive hazards model.
- Published in:
- Clinical Trials, 2016, v. 13, n. 2, p. 188, doi. 10.1177/1740774515614542
- By:
- Publication type:
- Article
12
Benefits and barriers to participating in longitudinal research of youth-onset type 2 diabetes: Results from the TODAY retention survey.
- Published in:
- Clinical Trials, 2016, v. 13, n. 2, p. 240, doi. 10.1177/1740774515613949
- By:
- Publication type:
- Article
13
Architecture design of a generic centralized adjudication module integrated in a web-based clinical trial management system.
- Published in:
- Clinical Trials, 2016, v. 13, n. 2, p. 223, doi. 10.1177/1740774515611889
- By:
- Publication type:
- Article
14
Should consent forms used in clinical trials be translated into the local dialects? A survey among past participants in rural Ghana.
- Published in:
- Clinical Trials, 2016, v. 13, n. 2, p. 234, doi. 10.1177/1740774515609290
- By:
- Publication type:
- Article
15
Identifying treatment effect heterogeneity in clinical trials using subpopulations of events: STEPP.
- Published in:
- Clinical Trials, 2016, v. 13, n. 2, p. 169, doi. 10.1177/1740774515609106
- By:
- Publication type:
- Article
16
Alignment of site versus adjudication committee–based diagnosis with patient outcomes: Insights from the Providing Rapid Out of Hospital Acute Cardiovascular Treatment 3 trial.
- Published in:
- Clinical Trials, 2016, v. 13, n. 2, p. 140, doi. 10.1177/1740774515601437
- By:
- Publication type:
- Article